2.80k followers • 20 symbols Watchlist by Motif Investing
Global adoption of minimally invasive procedures could spark new growth. The global minimally invasive surgery market is forecast to reach $35.5 billion by the end of 2016 with compound annual growth rate ("CAGR") of 8.2%.
Intuitive Surgical, Inc.
Boston Scientific Corporation
Smith & Nephew plc
Globus Medical, Inc.
Cardiovascular Systems, Inc.
K2M Group Holdings, Inc.
Mazor Robotics Ltd.
Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.
Investing.com - Intuitive Surgical (NASDAQ:ISRG) reported third quarter earnings that beat analysts' expectations on Thursday and revenue that topped forecasts.
Intuitive Surgical (ISRG) continues to benefit from da Vinci surgical system, strong global foothold and solid recurring revenue base. However, margin contraction continues to raise concern.
Boston Scientific (BSX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Align Technology (ALGN) is continuing with its winning streak of delivering a sturdy Invisalign Technology volume expansion across the company's entire customer base.
Better-than-expected performance at Instruments & Accessories segment and da Vinci procedure growth are likely to aided Intuitive Surgical (ISRG) in Q3 earnings.
Apart from the decent number of new jobs, the unemployment rate in the United States dropped 0.2 percentage points to hit a five-decade low of 3.5% last month.
Medtronic's (MDT) filing for both its InterStim products to gain FDA's PMA is its essential bid to boost its Pelvic Health & Gastric Therapies business.
Considering the weak penetration level in the international market, which is even less than 1%, Omnicell (OMCL) is rapidly exploring the uncharted overseas markets.
Stratasys' (SSYS) new 3D printer is especially beneficial for medical device companies, which require new ways to drive faster adoption of technologies and procedures.
This FDA designation is expected to bolster Medtronic's (MDT) Aortic, Peripheral & Venous line within the broader Cardiac and Vascular group.